Literature DB >> 10982382

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

S Rusconi1, S La Seta Catamancio, P Citterio, E Bulgheroni, F Croce, S H Herrmann, R E Offord, M Galli, M S Hirsch.   

Abstract

We studied the combined anti-human immunodeficiency virus type 1 (HIV-1) effects of a derivative of stroma-derived factor 1beta (SDF-1beta), Met-SDF-1beta, and a modified form of RANTES, aminooxypentane (AOP)-RANTES. The antiviral agents were tested singly or in combination at 95 and 99% virus inhibitory concentrations. Clinical R5 and X4 HIV-1 isolates were used. AOP-RANTES inhibited R5 but not X4 viruses, whereas Met-SDF-1beta had the opposite effect. Combinations of these compounds inhibited mixed infections with R5 and X4 viruses (95 to 99%), whereas single drugs were less inhibitory (32 to 61%). Combinations of R5 and X4 inhibitors are promising and deserve further evaluation.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10982382      PMCID： PMC102134          DOI： 10.1128/jvi.74.19.9328-9332.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  35 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

4.  The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; A Cara; R C Gallo; P Lusso
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

5.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

6.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

7.  Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.

Authors:  G Simmons; D Wilkinson; J D Reeves; M T Dittmar; S Beddows; J Weber; G Carnegie; U Desselberger; P W Gray; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

Authors:  A E Proudfoot; C A Power; A J Hoogewerf; M O Montjovent; F Borlat; R E Offord; T N Wells
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

9.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates.

Authors:  A Valentin; J Albert; E M Fenyö; B Asjö
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103
View more
  4 in total

1.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.

Authors:  Hirotomo Nakata; Seth M Steinberg; Yasuhiro Koh; Kenji Maeda; Yoshikazu Takaoka; Hirokazu Tamamura; Nobutaka Fujii; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 3.  Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Authors:  Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

4.  New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses.

Authors:  Stefano Rusconi; Mirko Lo Cicero; Ottavia Viganò; Francesca Sirianni; Elisabetta Bulgheroni; Stefania Ferramosca; Andrea Bencini; Antonio Bianchi; Lidia Ruiz; Cecilia Cabrera; Javier Martinez-Picado; Claudiu T Supuran; Massimo Galli
Journal:  Molecules       Date:  2009-05-22       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.